Biohaven Stock Rises on Strategic Licensing Deal

Biohaven Secures $795M Licensing Agreement

Biohaven Ltd. shares climbed 7% following a global strategic licensing agreement with SK Biopharmaceuticals. The deal, covering Biohaven's Kv7 ion channel platform and opakalim (an epilepsy treatment candidate), is valued up to $795 million. Biohaven will receive $400 million cash ($350M at closing, $50M in 2027), plus tiered royalties and up to $150 million in additional milestone payments. SK Biopharmaceuticals assumes future Kv7 program costs and leverages its commercial expertise.

Development Outlook and Market Impact

Opakalim, a lead Kv7 platform candidate, is in Phase 2/3 development for focal epilepsy, with topline results expected late 2026. This partnership bolsters Biohaven's financials and validates its Kv7 technology, simultaneously expanding SK Biopharmaceuticals' epilepsy portfolio. The agreement awaits regulatory and antitrust approvals.

Conclusion

This alliance provides significant funding for Biohaven's pipeline and strengthens SK Biopharmaceuticals' market presence. Observers will monitor opakalim's clinical progress and regulatory milestones.

FAQ

Q: Why did Biohaven's stock rise?
A: Biohaven's stock rose 7% due to a strategic licensing deal with SK Biopharmaceuticals for its Kv7 platform and opakalim.

Q: What is the deal's potential value?
A: The deal's potential value for Biohaven is up to $795 million, including cash, milestones, and royalties.

Source: Investing.com